ClinicalTrials.gg
CompletedNCT03280030Updated Mar 20, 2025Results posted

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

A Phase 2 interventional study of Midostaurin and Placebo in Acute Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 34 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies testing midostaurin in Leukemia, Myeloid, Acute — 2 open to participants now, 4 under way, none of them phase 3. midostaurin · Leukemia, Myeloid, Acute.

Enrollment
10th of 27
67 · median 34
Started
2018
with 5 others
Phase 2
11 of 27
none open now
Registered
19th of 27
by date
Lead sponsor
9 of 27
Novartis Pharmaceuticals

Among the 27 studies testing midostaurin in Leukemia, Myeloid, Acute, this one is the 10th largest by enrollment, is one of 6 that started in 2018, is one of 11 in phase 2, and was the 19th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

2 of the 27 studies testing midostaurin in Leukemia, Myeloid, Acute are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About midostaurin

midostaurin: first FDA approval 2017 (RYDAPT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing midostaurin in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This study evaluated the efficacy and safety of midostaurin in combination with daunorubicin/cytarabine induction, high dose cytarabine consolidation and midostaurin single agent continuation therapy in newly diagnosed patients with FLT3-mutated acute myeloid leukemia (AML).

Read the detailed description

This was a Phase II, multi-center trial consisting of two parts; Part 1: an open label, safety evaluation part in Japan only (minimum of three evaluable subjects) and Part 2: a double-blind, randomized, placebo-controlled part (60 subjects). Part 1 in Japan and Part 2 outside Japan were initiated simultaneously. Part 1 was conducted to evaluate the safety and tolerability of midostaurin in combination with daunorubicin/cytarabine induction and high-dose cytarabine consolidation in Japanese subjects and was a pre-requisite before allowing participation of Japan in Part 2. Data from Part 1 was reviewed by an Independent safety Committee (ISC) designated by the Sponsor. The ISC reviewed all available safety data in subjects from Japan up to the time of the safety review data cut-off date (6-Sep-2018). A meeting with the ISC was held on 25-Sep-2018: based on safety evaluation in three evaluable subjects, the ISC members recommended to start Part 2 in Japan.

Part 2 of the study included screening phase, treatment phase composed of up to 18 cycles of midostaurin/placebo treatment in combination with chemotherapy (daunorubicin and cytarabine) during induction and consolidation and alone during continuation and 30 days safety follow up from last dose of study treatment (daunorubicin or cytarabine or midostaurin/placebo); and follow up phase for continued remission and survival follow-up (until 36 months after Day 1 of the last subject). Subjects who provided written informed consent were screened for eligibility during the period up to 7 days immediately prior to starting chemotherapy (Day 1). The subject was randomized at Day 8 to receive either midostaurin or placebo only if FLT3 status was mutated. Treatment phase included induction, consolidation and continuation therapies.

Induction therapy: All screened subjects started induction therapy with chemotherapy from Day 1 to Day 7, while the FLT3 mutation status was being determined. Subjects who achieved CR already with induction Cycle 1 went directly to consolidation therapy without a second cycle of induction therapy. Subjects who did not achieve CR with one cycle of induction received a second induction cycle with same treatment as in Cycle 1. Subjects who did not achieve CR after induction 2 discontinued the study treatment and were followed in safety follow up and survival follow-up.

Consolidation therapy: Subjects who achieved a CR after 1 or 2 cycles of induction received consolidation therapy with 3 cycles of high-dose cytarabine for the Japan Adult Leukemia Study Group (JALSG) regimen and 4 cycles of high-dose cytarabine as tolerated for the Randomized AML Trial In FLT3+ subjects \<60 Years old (RATIFY) regimen. Subjects received midostaurin/placebo, orally twice a day, on Days 8 to 21 of each cycle. Each consolidation cycle began within two weeks following hematopoietic recovery (ANC ≥ 1.0 x 109/L, platelet count ≥ 100 x 109/L) but no sooner than four weeks from the beginning of the previous cycle.

Continuation therapy: After hematopoietic recovery (ANC ≥ 1.0 x 109/L, platelet count ≥ 100 x 109/L) following the final cycle of consolidation but no sooner than 14 days after the last dose of midostaurin/placebo during the last consolidation cycle, subjects who maintained a CR received up to 12 cycles (28 days/cycle) of continuous therapy with midostaurin or placebo twice a day. Safety was assessed in this treatment phase for each subject until 30 days after the end of treatment (EOT) and included routine safety monitoring.

The follow-up phases included post treatment follow-up and survival follow-up. During post-treatment follow-up, all subjects continued to be assessed for relapse i.e. every 2 months during years 1 and 2, every 3 months on year 3 and 4 and then yearly and at time of relapse until relapse, withdrawal of consent, death, loss to follow up, or end of study, whichever was earlier following the end of study treatment for any reason other than persistent AML. Subjects who discontinued study treatment due to persistent AML or relapse and the post treatment follow-up phase due to relapse entered a survival follow-up period during which survival was recorded every 3 months. Survival information was obtained by clinical visits or telephone calls or other means until death, withdrawal of consent, lost to follow-up or end of study, whichever was earlier.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • midostaurin
  • PKC412
  • cytarabine
  • daunorubicin
  • acute myeloid leukemia
  • combination treatment
  • FLT3
  • acute myeloid leukemia (AML)
  • acute myelogenous leukemia (AML)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of AML (≥ 20% blasts in the bone marrow based on WHO 2016 classification). Patients with APL (acute promyelocytic leukemia) with PML-RARA are not eligible
  • Documented presence of an ITD and/or TKD activating mutation in the FLT3 gene, as determined by analysis in a Novartis designated laboratory An exception will be patients who are enrolled into the part 1 in Japan, who may be treated with midostaurin irrespective of AML FLT3 genotype.
  • Patients must meet the following laboratory value criteria that indicate adequate organ function at the screening visit:

    • Estimated ≥ 30 ml/min
    • Total ≤ 1.5 x , except in the setting of isolated Gilbert syndrome
    • (AST) ≤ 3.0 x ULN
    • Alanine transaminase (ALT) ≤ 3.0 x ULN
  • Suitability for intensive chemotherapy in the judgment of the investigator

Exclusion criteria

Exclusion Criteria:

  • Neurologic symptoms suggestive of CNS leukemia unless CNS leukemia has been excluded by a lumbar puncture. Patients with CSF fluid positive for AML blasts are not eligible
  • Developed therapy-related AML after prior radiotherapy (RT) or chemotherapy for another cancer or disorder
  • Known to midostaurin, cytarabine or daunorubicin or to any of the of midostaurin/placebo, cytarabine or daunorubicin
  • Abnormal chest X-ray unless the abnormality represents a non-active, or non- finding, such as scarring (subjects with controlled non active lung infection are eligible)
  • Known impairment of gastrointestinal (GI) function or GI disease that might alter significantly the absorption of midostaurin
  • Cardiac or cardiac repolarization abnormality
  • Pregnant or nursing (lactating) women
  • Women of , unless they are using highly effective methods of during dosing and for 4 months after stopping medication
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Midostaurin

    Patients took study drug on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.

    Drug: Midostaurin

  • Placebo comparator
    Placebo

    Patients took placebo on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.

    Drug: Placebo

Interventions

  • Midostaurin 50 mg \[two 25 mg capsules\] were administered twice per day by mouth on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.

    Also known as: PKC412

  • DrugPlacebo

    Placebo, two capsules, were administered twice per day by mouth on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.

06

What researchers measure

Primary outcomes

  1. Percentage of Safety Events (Part 1, Japan Only)

    Percentage of Safety Events, defined as death or serious adverse event leading to treatment discontinuation that occurs on or before Day 21 of the first Consolidation cycle. This was determined by the Independent Safety Committee (ISC) to be definitely or probably related to midostaurin. Percentage was calculated based on the percentage of subjects with safety event out of 3 evaluable subjects in Part 1.

    Time frame: up to Day 21 of the first Consolidation cycle; cycle = 28 days

  2. Event Free Survival (EFS) (Part 2 - Randomized, Controlled)

    Event Free survival is defined as the time from the date of randomization until an EFS event is observed. An EFS event is defined as a failure to obtain a complete remission (CR) within an induction 2, relapse after CR, or death due to any cause, whichever occurs first. The objective was to evaluate the efficacy based on EFS of midostaurin versus placebo in combination with daunorubicin/cytarabine induction, with high-dose cytarabine consolidation, and with midostaurin single agent continuation therapy in newly diagnosed patients with FLT3-mutated AML.

    Time frame: up to 3 years after last patient started treatment

Secondary outcomes

  1. Overall Survival

    Overall survival defined as the time from the date of randomization to date of death due to any cause

    Time frame: up to 3 years after last patient started treatment

  2. Percentage of Participants With Complete Remission (CR)

    Complete Remission is defined as the percentage of participants with a CR according to Chelson Criteria, at various timepoints

    Time frame: up to 3 years after last patient started treatment

  3. Percentage of Participants With Cumulative Incidence of Relapse (CIR)

    CIR (only for patients who achieved CR after study treatment initiation), is measured from the date of first CR to relapse or death due to AML, whichever occurs first.

    Time frame: up to 3 years after last patient started treatment

  4. Pharmakinetics (PK) for Midostaurin: AUClast & AUC0-t

    Evaluate AUClast \& AUC0-t PK parameters for midostaurin. AUClast: The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1) AUC0-t: The area under the curve (AUC) from time zero to a measurable concentration sampling time (t) (mass x time x volume-1).

    Time frame: Induction Phase: Pre-dose and 1, 3, 6 and 12 hours post dose in Cycle 1 Day 8

  5. Pharmakinetics (PK) for Midostaurin: Cmax

    Evaluate Cmax parameter for midostaurin. Cmax: The maximum (peak) observed plasma drug concentration after the first dose administration of midostaurin (mass x volume-1).

    Time frame: Induction Phase: Pre-dose and 1, 3, 6 and 12 hours post dose in Cycle 1 Day 8

  6. Metabolite CGP52421: PK Parameters AUClast, AUC0-t

    Evaluate the pharmacokinetic of major metabolite of midostaurin CGP52421. AUClast: The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1) AUC0-t: The area under the curve (AUC) from time zero to a measurable concentration sampling time (t) (mass x time x volume-1).

    Time frame: Induction Phase: Cycle 1 Day 8

  7. Metabolite CGP52421: PK Parameter Cmax

    Evaluate the pharmacokinetic of major metabolite of midostaurin CGP52421: Cmax. Cmax: The maximum (peak) observed plasma drug concentration after the first dose administration of midostaurin (mass x volume-1).

    Time frame: Induction Phase: Cycle 1 Day 8

  8. Metabolite CGP62221: PK Parameters: AUClast, AUC0-t

    Evaluate the pharmacokinetic of major metabolite of Midostaurin CGP62221 PK parameters AUClast, AUC0-t

    Time frame: Induction Phase: Cycle 1 Day 8

  9. Metabolite CGP62221: PK Parameter: Cmax

    Evaluate the pharmacokinetic of major metabolite of Midostaurin CGP62221 PK parameter Cmax. Cmax: The maximum (peak) observed plasma drug concentration after the first dose administration of midostaurin (mass x volume-1).

    Time frame: Induction Phase: Cycle 1 Day 8

  10. Change From Baseline in Quality of Life (QoL) Per European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30

    The EORTC QLQ-C30 is a 30-item questionnaire with multi-item scales and single-item measures, including five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea/vomiting, and pain), six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact), and a global health status/QoL scale. Scores range from 0 to 100, with higher scores indicating higher response levels. High functional scale scores denote healthy functioning, high global QoL scores indicate high QoL, and high symptom scores reflect high symptom levels. Scoring follows the EORTC Scoring Manual, reported by absolute change from baseline. EOI = End of Induction; EOCons = End of Consolidation; EOCont = End of Continuation; EOT = End of Treatment.

    Time frame: EOI: up to 1.84 months (after 2 cycles); EOCons: up to 5.52 months (after 4 cycles); EOCont: up to 16.56 months (after 12 cycles); EOT: up to 16.56 months maximum, depending on treatment duration; each cycle = 28 days

  11. Quality of Life (QoL) Per Patient Global Impression of Change (PGIC)

    The PGIC is a single self-reported item that asks about change in status of subject's overall satisfaction with medication since starting the standalone study. The specific wording of the PGIC is "Directions: Circle the one number that best describes how your overall satisfaction with your medication had changed since starting the study": "Very much improved" =1; "Much improved" =2; "Minimally improved" =3; "No change" =4; "Minimally worse" =5; "Much worse" =6; "Very much worse" =7. PGI-C questions have been widely used to assess the patient perspective of improvement in clinical trials and have shown clinical validity in a variety of indications, including depression, urinary incontinence and adult asthma and the PGIC score determined frequencies and percentages by scheduled timepoint. EOI = End of Induction; EOCons = End of Consolidation; EOCont = End of Continuation; EOT = End of Treatment.

    Time frame: EOI: up to 1.84 months (after 2 cycles); EOCons: up to 5.52 months (after 4 cycles); EOCont: up to 16.56 months (after 12 cycles); EOT: up to 16.56 months maximum, depending on treatment duration; each cycle = 28 days

07

Results

Posted Feb 11, 2025

Participant flow

Part 1 of the study enrolled 5 Japan adult subjects with newly diagnosed (ND) FLT3-mutated or non-mutated AML. Part 2 randomized 62 adult subjects with ND FLT3-mutated AML. The efficacy analysis was on the 62 randomized subjects in Part 2. The safety analysis was considered separately on 5 subjects in Part 1 \& 61 out of 62 randomized subjects in Part 2, as 1 subject did not receive randomized treatment (placebo). The PK analysis was on subjects treated with midostaurin in Part 1 or Part 2.

Part 1 - Safety Evaluation
Participant flow — Part 1 - Safety Evaluation
MilestoneMidostaurin: Part 1 (Japan Only)Midostaurin: Part 2Placebo: Part 2
Started500
Completed000
Not completed500
Withdrew: Physician decision200
Withdrew: Disease progression100
Withdrew: Adverse event200
Part 2 - Efficacy
Participant flow — Part 2 - Efficacy
MilestoneMidostaurin: Part 1 (Japan Only)Midostaurin: Part 2Placebo: Part 2
Started03032
Randomized, not treated001
Completed044
Not completed02628
Withdrew: Adverse event046
Withdrew: Death030
Withdrew: Physician decision01016
Withdrew: Withdrawal by subject021
Withdrew: Progressive disease075

Outcome measures

PrimaryPercentage of Safety Events (Part 1, Japan Only)

Percentage of Safety Events, defined as death or serious adverse event leading to treatment discontinuation that occurs on or before Day 21 of the first Consolidation cycle. This was determined by the Independent Safety Committee (ISC) to be definitely or probably related to midostaurin. Percentage was calculated based on the percentage of subjects with safety event out of 3 evaluable subjects in Part 1.

Time frame:
up to Day 21 of the first Consolidation cycle; cycle = 28 days
Reported as:
Number · Participants
Percentage of Safety Events (Part 1, Japan Only)
ParticipantsMidostaurin: Part 1 (Japan Only)Midostaurin: Part 2Placebo: Part 2
Experienced at least 1 adverse event (AE)5——
Safety events determined by ISC related to midostaurin (n = 3, 0, 0)0——
PrimaryEvent Free Survival (EFS) (Part 2 - Randomized, Controlled)

Event Free survival is defined as the time from the date of randomization until an EFS event is observed. An EFS event is defined as a failure to obtain a complete remission (CR) within an induction 2, relapse after CR, or death due to any cause, whichever occurs first. The objective was to evaluate the efficacy based on EFS of midostaurin versus placebo in combination with daunorubicin/cytarabine induction, with high-dose cytarabine consolidation, and with midostaurin single agent continuation therapy in newly diagnosed patients with FLT3-mutated AML.

Time frame:
up to 3 years after last patient started treatment
Reported as:
Median · Months
Event Free Survival (EFS) (Part 2 - Randomized, Controlled)
MonthsMidostaurin: Part 2Placebo: Part 2
Event Free Survival (EFS) (Part 2 - Randomized, Controlled)7.6 (3.6 to NA)NA (8.2 to NA)
Statistical analysis
  • Midostaurin: Part 2 vs Placebo: Part 2 · Hazard ratio, log: 1.326 · 95% CI 0.624 to 2.818
SecondaryOverall Survival

Overall survival defined as the time from the date of randomization to date of death due to any cause

Time frame:
up to 3 years after last patient started treatment
Reported as:
Median · Months
Overall Survival
MonthsMidostaurin: Part 2Placebo: Part 2
Overall SurvivalNA (16.8 to NA)NA (18.8 to NA)
SecondaryPercentage of Participants With Complete Remission (CR)

Complete Remission is defined as the percentage of participants with a CR according to Chelson Criteria, at various timepoints

Time frame:
up to 3 years after last patient started treatment
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Remission (CR)
Percentage of participantsMidostaurin: Part 2Placebo: Part 2
Overall CR70.0 (50.60 to 85.27)78.1 (60.03 to 90.72)
Morphologic CR with incomplete platelet count recovery (CRp)6.7 (0.86 to 22.07)0.0 (0.00 to 10.89)
End of Induction cycle 1 (C1) CR56.7 (37.43 to 74.54)65.6 (46.81 to 81.43)
End of Induction C1: Morphologic CRp3.3 (0.08 to 17.22)0.0 (0.00 to 10.89)
End of Induction cycle 2 (C2) CR13.3 (3.76 to 30.72)9.4 (1.98 to 25.02)
End of Induction C2: Morphologic CRp3.3 (0.08 to 17.00)0.0 (0.00 to 10.89)
End of Consolidation CR36.7 (19.93 to 56.14)43.8 (26.36 to 62.34)
End of Consolidation Morphologic CRp3.3 (0.08 to 17.22)9.4 (1.98 to 25.02)
After treatment discontinuation CR10.0 (2.11 to 26.53)3.1 (0.08 to 16.22)
After treatment discontinuation Morphologic CRp0.0 (0.00 to 11.57)6.3 (0.77 to 20.81)
SecondaryPercentage of Participants With Cumulative Incidence of Relapse (CIR)

CIR (only for patients who achieved CR after study treatment initiation), is measured from the date of first CR to relapse or death due to AML, whichever occurs first.

Time frame:
up to 3 years after last patient started treatment
Reported as:
Count of participants · Participants
Percentage of Participants With Cumulative Incidence of Relapse (CIR)
ParticipantsMidostaurin: Part 2Placebo: Part 2
Percentage of Participants With Cumulative Incidence of Relapse (CIR)2125
SecondaryPharmakinetics (PK) for Midostaurin: AUClast & AUC0-t

Evaluate AUClast \& AUC0-t PK parameters for midostaurin. AUClast: The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1) AUC0-t: The area under the curve (AUC) from time zero to a measurable concentration sampling time (t) (mass x time x volume-1).

Time frame:
Induction Phase: Pre-dose and 1, 3, 6 and 12 hours post dose in Cycle 1 Day 8
Reported as:
Geometric mean · ng*hr/mL
Pharmakinetics (PK) for Midostaurin: AUClast & AUC0-t
ng*hr/mLMidostaurin: Part 2
AUClast17900 ± 53.5
AUC0-t19200 ± 49.0
SecondaryPharmakinetics (PK) for Midostaurin: Cmax

Evaluate Cmax parameter for midostaurin. Cmax: The maximum (peak) observed plasma drug concentration after the first dose administration of midostaurin (mass x volume-1).

Time frame:
Induction Phase: Pre-dose and 1, 3, 6 and 12 hours post dose in Cycle 1 Day 8
Reported as:
Geometric mean · ng/mL
Pharmakinetics (PK) for Midostaurin: Cmax
ng/mLMidostaurin: Part 2
Pharmakinetics (PK) for Midostaurin: Cmax2420 ± 46.5
SecondaryMetabolite CGP52421: PK Parameters AUClast, AUC0-t

Evaluate the pharmacokinetic of major metabolite of midostaurin CGP52421. AUClast: The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1) AUC0-t: The area under the curve (AUC) from time zero to a measurable concentration sampling time (t) (mass x time x volume-1).

Time frame:
Induction Phase: Cycle 1 Day 8
Reported as:
Geometric mean · ng*hr/mL
Metabolite CGP52421: PK Parameters AUClast, AUC0-t
ng*hr/mLMidostaurin: Part 2
AUClast754 ± 116
AUC0-t876 ± 92.3
SecondaryMetabolite CGP52421: PK Parameter Cmax

Evaluate the pharmacokinetic of major metabolite of midostaurin CGP52421: Cmax. Cmax: The maximum (peak) observed plasma drug concentration after the first dose administration of midostaurin (mass x volume-1).

Time frame:
Induction Phase: Cycle 1 Day 8
Reported as:
Geometric mean · ng/mL
Metabolite CGP52421: PK Parameter Cmax
ng/mLMidostaurin: Part 2
Metabolite CGP52421: PK Parameter Cmax98.6 ± 83.5
SecondaryMetabolite CGP62221: PK Parameters: AUClast, AUC0-t

Evaluate the pharmacokinetic of major metabolite of Midostaurin CGP62221 PK parameters AUClast, AUC0-t

Time frame:
Induction Phase: Cycle 1 Day 8
Reported as:
Geometric mean · ng*hr/mL
Metabolite CGP62221: PK Parameters: AUClast, AUC0-t
ng*hr/mLMidostaurin: Part 2
AUClast1430 ± 223
AUC0-t1730 ± 182
SecondaryMetabolite CGP62221: PK Parameter: Cmax

Evaluate the pharmacokinetic of major metabolite of Midostaurin CGP62221 PK parameter Cmax. Cmax: The maximum (peak) observed plasma drug concentration after the first dose administration of midostaurin (mass x volume-1).

Time frame:
Induction Phase: Cycle 1 Day 8
Reported as:
Geometric mean · ng/mL
Metabolite CGP62221: PK Parameter: Cmax
ng/mLMidostaurin: Part 2
Metabolite CGP62221: PK Parameter: Cmax196 ± 159
SecondaryChange From Baseline in Quality of Life (QoL) Per European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30

The EORTC QLQ-C30 is a 30-item questionnaire with multi-item scales and single-item measures, including five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea/vomiting, and pain), six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact), and a global health status/QoL scale. Scores range from 0 to 100, with higher scores indicating higher response levels. High functional scale scores denote healthy functioning, high global QoL scores indicate high QoL, and high symptom scores reflect high symptom levels. Scoring follows the EORTC Scoring Manual, reported by absolute change from baseline. EOI = End of Induction; EOCons = End of Consolidation; EOCont = End of Continuation; EOT = End of Treatment.

Time frame:
EOI: up to 1.84 months (after 2 cycles); EOCons: up to 5.52 months (after 4 cycles); EOCont: up to 16.56 months (after 12 cycles); EOT: up to 16.56 months maximum, depending on treatment duration; each cycle = 28 days
Reported as:
Mean · scores on a scale
Change From Baseline in Quality of Life (QoL) Per European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30
scores on a scaleMidostaurin: Part 2Placebo: Part 2
EOI: Global health status (GHS):GHS27.8 ± 31.030.0 ± 16.67
EOCons: GHS:GHS20.8 ± 11.4937.1 ± 24.54
EOCont: GHS:GHS28.3 ± 22.5227.8 ± 10.09
EOT:GHS:GHS25.5 ± 21.9428.8 ± 23.33
SecondaryQuality of Life (QoL) Per Patient Global Impression of Change (PGIC)

The PGIC is a single self-reported item that asks about change in status of subject's overall satisfaction with medication since starting the standalone study. The specific wording of the PGIC is "Directions: Circle the one number that best describes how your overall satisfaction with your medication had changed since starting the study": "Very much improved" =1; "Much improved" =2; "Minimally improved" =3; "No change" =4; "Minimally worse" =5; "Much worse" =6; "Very much worse" =7. PGI-C questions have been widely used to assess the patient perspective of improvement in clinical trials and have shown clinical validity in a variety of indications, including depression, urinary incontinence and adult asthma and the PGIC score determined frequencies and percentages by scheduled timepoint. EOI = End of Induction; EOCons = End of Consolidation; EOCont = End of Continuation; EOT = End of Treatment.

Time frame:
EOI: up to 1.84 months (after 2 cycles); EOCons: up to 5.52 months (after 4 cycles); EOCont: up to 16.56 months (after 12 cycles); EOT: up to 16.56 months maximum, depending on treatment duration; each cycle = 28 days
Reported as:
Number · Participants
Quality of Life (QoL) Per Patient Global Impression of Change (PGIC)
ParticipantsMidostaurin: Part 2Placebo: Part 2
EOI: Very much improved10
EOI: Much improved21
EOI: Minimally improved30
EOI: No change11
EOI: Minimally worse01
EOCons: Very much improved11
EOCons: Much improved23
EOCons: Minimally improved24
EOCons: No change12
EOCons: Minimally worse01
EOCont: Very much improved32
EOCont: Much improved04
EOCont: Minimally improved10
EOCont: No change10
EOT: Very much improved53
EOT: Much improved48
EOT: Minimally improved64
EOT: No change33
EOT: Minimally worse02
Post-hocAll Collected Deaths

Pre-treatment deaths were collected from screening visit up to the first day of treatment, for a maximum duration of 21 days. Participants who died during the screening period are considered as screen failures. On-treatment deaths were collected from start of treatment (FPFT) up to 30 days after study drug discontinuation, for a maximum duration of approx. 55 months. Post-treatment survival follow-up deaths were collected after the on-treatment period up to approx. 36 months. Participants who did not die during the on-treatment period and had not stopped study participation at the time of data cut-off (when study was terminated) were censored.

Time frame:
Start of study treatment up to 30 days post-treatment for approx. 1 year, prior to study treatment (before randomization) up to LPLV, approx. 55 months
Reported as:
Count of participants · Participants
All Collected Deaths
ParticipantsMidostaurin: Part 1 (Japan Only)Midostaurin: Part 2Placebo: Part 2Other Participants
Total Deaths in study31077
Deaths on-treatment1310
Post-treatment survival follow-up deaths2760
Deaths - Not randomized to any treatment but received chemotherapy0006
Deaths - Randomized to placebo but did not receive drug0001

Adverse events

Collected over Adverse events were collected from first dose of study treatment to 30 days after last dose of study medication (on-treatment), up to approx. 55 months. Deaths were collected in the post-treatment survival follow up from 31 days after last dose of study medication until the end of the study, up to approx. 36 months. These are not considered AEs. Non-serious events are listed at a 4.99% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Midostaurin: Part 1 (Japan Only) (On-treatment)1/5 (20%)2/5 (40%)5/5 (100%)
Midostaurin: Part 2 (On-treatment)3/30 (10%)12/30 (40%)30/30 (100%)
Placebo Part 2 (On-treatment)1/31 (3.2%)10/31 (32.3%)31/31 (100%)
Midostaurin: Part 1 (Japan Only) (Post-treatment Survival Follow-up)2/4 (50%)——
Midostaurin: Part 2 (Post-treatment Survival Follow-up)7/27 (25.9%)——
Placebo: Part 2 (Post-treatment Survival Follow-up)6/30 (20%)——
Other Participants7/7 (100%)——
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventMidostaurin: Part 1 (Japan Only) (On-treatment)Midostaurin: Part 2 (On-treatment)Placebo Part 2 (On-treatment)Midostaurin: Part 1 (Japan Only) (Post-treatment Survival Follow-up)Midostaurin: Part 2 (Post-treatment Survival Follow-up)Placebo: Part 2 (Post-treatment Survival Follow-up)Other Participants
Febrile neutropeniaBlood and lymphatic system disorders1/52/301/31————
Cardiac failure acuteCardiac disorders1/50/300/31————
Multiple organ dysfunction syndromeGeneral disorders1/50/300/31————
PneumoniaInfections and infestations1/55/302/31————
SepsisInfections and infestations1/53/301/31————
Septic shockInfections and infestations0/52/301/31————
PyrexiaGeneral disorders0/51/302/31————
ThrombocytopeniaBlood and lymphatic system disorders0/51/301/31————
Cardiac failureCardiac disorders0/51/300/31————
Cardio-respiratory arrestCardiac disorders0/51/300/31————
Most frequent other events
Showing 10 of 146
Most frequent other events
EventMidostaurin: Part 1 (Japan Only) (On-treatment)Midostaurin: Part 2 (On-treatment)Placebo Part 2 (On-treatment)Midostaurin: Part 1 (Japan Only) (Post-treatment Survival Follow-up)Midostaurin: Part 2 (Post-treatment Survival Follow-up)Placebo: Part 2 (Post-treatment Survival Follow-up)Other Participants
NauseaGastrointestinal disorders5/517/3017/31————
Febrile neutropeniaBlood and lymphatic system disorders4/525/3021/31————
MalaiseGeneral disorders4/53/302/31————
PyrexiaGeneral disorders4/513/3019/31————
DiarrhoeaGastrointestinal disorders2/520/3017/31————
AnaemiaBlood and lymphatic system disorders3/517/3015/31————
StomatitisGastrointestinal disorders3/59/3010/31————
VomitingGastrointestinal disorders3/58/3014/31————
Decreased appetiteMetabolism and nutrition disorders3/56/307/31————
HypoalbuminaemiaMetabolism and nutrition disorders3/52/301/31————

Baseline characteristics

Full Analysis Set (FAS): The FAS comprised of all subjects to whom study drug (midostaurin/placebo) had been assigned by randomization. Therefore, all Japanese subjects treated during Part 1 were not eligible for the FAS.

Age, Customized
Age, Customized(Participants)Midostaurin: Part 1 (Japan Only)Midostaurin: Part 2Placebo: Part 2Total
<60 years3272353
60 - <65 years2259
≥65 years0145
Sex: Female, Male
Sex: Female, Male(Participants)Midostaurin: Part 1 (Japan Only)Midostaurin: Part 2Placebo: Part 2Total
Female2161735
Male3141532
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Midostaurin: Part 1 (Japan Only)Midostaurin: Part 2Placebo: Part 2Total
Japanese5121229
Korean04610
Chinese031013
Vietnamese0145
Missing0101
White0909
08

Study locations

34 sites
  • Novartis Investigative Site
    Pokfulam, Hong Kong
  • Novartis Investigative Site
    Nagoya, Aichi 466-8650, Japan
  • Novartis Investigative Site
    Toyoake city, Aichi 470 1192, Japan
  • Novartis Investigative Site
    Kashiwa, Chiba 277 8577, Japan
  • Novartis Investigative Site
    Fukuoka city, Fukuoka 812-8582, Japan
  • Novartis Investigative Site
    Fukushima city, Fukushima 960 1295, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 064 0804, Japan
  • Novartis Investigative Site
    Isehara, Kanagawa 259-1193, Japan
  • Novartis Investigative Site
    Nagasaki-city, Nagasaki 852-8501, Japan
  • Novartis Investigative Site
    Okayama city, Okayama 701-1192, Japan
  • Novartis Investigative Site
    Osaka Sayama, Osaka 589 8511, Japan
  • Novartis Investigative Site
    Osaka-city, Osaka 543-8555, Japan
  • Novartis Investigative Site
    Hamamatsu, Shizuoka 432-8580, Japan
  • Novartis Investigative Site
    Shimotsuke, Tochigi 329-0498, Japan
  • Novartis Investigative Site
    Bunkyo ku, Tokyo 113-8677, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 113-8603, Japan
  • Novartis Investigative Site
    Shinagawa ku, Tokyo 141 8625, Japan
  • Novartis Investigative Site
    Aomori, 030 8553, Japan
  • Novartis Investigative Site
    Fukuoka, 810-8563, Japan
  • Novartis Investigative Site
    Kochi, 781 8555, Japan
  • Novartis Investigative Site
    Kyoto, 606 8507, Japan
  • Novartis Investigative Site
    Osaka, 534-0021, Japan
  • Novartis Investigative Site
    Yamagata, 990 9585, Japan
  • Novartis Investigative Site
    Seoul, Seocho Gu 06591, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03722, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06351, Korea, Republic of
  • Novartis Investigative Site
    Moscow, 123182, Russian Federation
  • Novartis Investigative Site
    Moscow, 125284, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 197341, Russian Federation
  • Novartis Investigative Site
    Putzu City, Chiayi Hsien 61363, Taiwan
  • Novartis Investigative Site
    Kaohsiung, 83301, Taiwan
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Taoyuan, 33305, Taiwan
  • Novartis Investigative Site
    Hanoi, 100000, Vietnam
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Nov 2022, 55 months.

Results were first posted in Feb 2025, 2 years 2 months after primary completion.

Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's 55 months is above that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2017
First posted
Sep 12, 2017
StartActual
Apr 6, 2018
Primary completionActual
Nov 14, 2022
CompletionActual
Nov 14, 2022
Results first posted
Feb 11, 2025
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03280030
Responsible party
Sponsor
First posted
Sep 12, 2017
Start date
Apr 6, 2018
Primary completion
Nov 14, 2022
Completion
Nov 14, 2022
Results posted
Feb 11, 2025
Last update
Mar 20, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Midostaurin

Start the discussion